Skip to main content
BrainCited

Comparing the Efficacy of Combined Intralesional Triamcinolone Acetonide With Topical Calcipotriol Versus Intralesional Triamcinolone Acetonide Monotherapy in Scalp and Beard Alopecia Areata: Results From a Randomized Single-Blinded Clinical Trial.

Thoyyib Parammal Karat, Anupama Bains, Abhishek Bhardwaj, Saurabh Singh, Anil Budania et al.
RCT Journal of cutaneous medicine and surgery 2025
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'pmid\u003D39878244'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo de estudio
Randomized Controlled Trial
Tamaño de muestra
73
Población
Patients with scalp and beard alopecia areata (179 patches)
Duración
12 weeks
Intervención
Comparing the Efficacy of Combined Intralesional Triamcinolone Acetonide With Topical Calcipotriol Versus Intralesional Triamcinolone Acetonide Monotherapy in Scalp and Beard Alopecia Areata: Results IL triamcinolone every 4 weeks + calcipotriol twice daily
Comparador
IL triamcinolone acetonide alone
Resultado primario
Hair density (regrowth scale)
Dirección del efecto
Positive
Riesgo de sesgo
Moderate

Abstract

BACKGROUND: Intralesional (IL) steroids are the first-line treatment option for localized alopecia areata (AA). The present study aimed to compare the efficacy of topical calcipotriol with IL triamcinolone acetonide versus IL triamcinolone acetonide alone in AA. METHODS: This randomized single-blinded clinical trial was conducted in a dermatology outpatient department. Both groups A and B received IL triamcinolone acetonide injections every 4 weeks for 12 weeks. Group A also received twice-daily topical calcipotriol. Follow-up was done every 4 weeks till 12 weeks. The primary outcome parameter was hair density assessment using a hair regrowth scale (RGS). Other parameters were the presence or absence of poor clinical response (less than 50% hair density), regrowth patterns, dermoscopy features, and adverse effects. RESULTS: Seventy-three (179 patches) patients completed the study. RGS and patches with more than 50% terminal hair regrowth significantly improved in both the groups beginning in the fourth week and going forward (P-value: .001, .001). The two treatment groups exhibited no statistically significant difference in terminal hair density (P values: .930, .616, .178). However, subgroup analysis showed a statistically significant difference in scalp patches of group A compared to group B in the 12th week of the study (P = .018) but not in beard patches (P-value: .527). Group A exhibited more irritation with a reduced incidence of atrophy. CONCLUSION: The addition of topical calcipotriol to IL steroid showed increased efficacy in scalp patches of AA but not in beard patches. Also, the incidence of atrophy was lower in the combination group.

TL;DR

The addition of topical calcipotriol to IL steroid showed increased efficacy in scalp patches of AA but not in beard patches, and the incidence of atrophy was lower in the combination group.

Used In Evidence Reviews

Similar Papers